Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03387722
Other study ID # D2287R00124
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 31, 2017
Est. completion date January 3, 2019

Study information

Verified date September 2020
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

SevEos is a cross-sectional, multi-center, non-interventional study aimed to describe the treatment patterns in 250 severe asthma patients across the Gulf region. In addition, the study will determine the current level of asthma control and quality of life in these patients; describe the exacerbation patterns; and determine the current levels of blood eosinophils for the enrolled patients.


Description:

The primary objective of this study is to describe the treatments patterns of severe asthmatic patients across four Gulf countries during the past year.

Secondary Objectives

1. To determine the current level of asthma control in these patients. In addition, a comparison of uncontrolled asthma between those with a eosinophilic count ≥ 300 cell/μl and those with an elevated eosinophilic count less than that.

2. To determine the current and past year levels of blood eosinophils, and the percentage of patients with elevated eosinophilic level ≥ 150 cells/μL and ≥ 300 cells/μL

3. To describe the frequency of exacerbations during the past year.

4. To assess the current quality of life (QoL) of these patients.

5. To determine the past year levels of serum IgE.

6. Exploratory objective: To determine the past year levels of other inflammatory biomarkers like periostin and fraction of exhaled nitric oxide (FeNO).


Recruitment information / eligibility

Status Completed
Enrollment 253
Est. completion date January 3, 2019
Est. primary completion date January 3, 2019
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria:

To be included in this study, patients (both male and female) must fulfill all of the following criteria:

1. Age above 12 years.

2. Body weight of =40 kg.

3. Diagnosed by a physician with severe asthma, who requires regular treatment with medium or high dosage Inhaled Corticosteroids (ICS) (patients aged 12-17 years) OR high-dosage ICS ( plus Long-Acting Beta Agonist (LABA) for at least 1 year before enrolment.

[Note that the value of the medium/high dosage is dependent on the type of ICS

Exclusion Criteria:

Patients who meet any of the following criteria are ineligible to participate in the study:

1. Patient refuses to consent.

2. Another clinically important pulmonary disease is considered to be the primary diagnosis, other than severe asthma (i.e.: COPD, major bronchiectasis, active tuberculosis, and other conditions considered by the principal investigator).

3. Mentally disabled patient or inability to understand the study questions.

4. Unable to read/write.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Oman Research Site Muscat
United Arab Emirates Research Site Dubai

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

Oman,  United Arab Emirates, 

Outcome

Type Measure Description Time frame Safety issue
Other Periostin level Mean or median of levels of Last Periostin level during the past year 1 year
Other FeNO level Mean or median of levels Last FeNO level during the past year 1 Year
Primary Asthma treatment and its patterns through generic names. Changes in Asthma treatment stages during the last year based on the number of prescribed:
Short-acting: muscarinic antagonists (SAMA),
long-acting muscarinic antagonists (LAMA),
Long-acting Beta agonist (LABA),
Corticosteroids (Inhaled(ICS), Oral(OCS) & Parental),
Theophylline,
Biologics.
1 year
Primary Asthma treatment and its patterns through dosage Changes in Asthma treatment stages during the last year based on the dosage:
Short-acting: muscarinic antagonists (SAMA),
long-acting muscarinic antagonists (LAMA),
Long-acting Beta agonist (LABA),
Corticosteroids (Inhaled(ICS), Oral(OCS) & Parental),
Theophylline,
Biologics.
1 Year
Secondary Asthma Control Asthma control will be assed using "The Asthma Control Questionnaire". The questionnaire was developed by Elizabeth Juniper( MCSP, MSc Professor, 20 Marcuse Fields) Bosham, West Sussex PO18 8NA, England), to measure both the adequacy of asthma control and change in asthma control, which occurs either spontaneously or as a result of treatment.
Patients are asked to respond to questions on a 7-point scale (0=no impairment, 6= maximum impairment). The questions are equally weighted and the ACQ score is the mean of the 7 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). A change or difference in score of 0.5 is the smallest that can be considered clinically important.
1 year
Secondary Exacerbations Collection of exacerbations records based on history of documented Emergency Room(ER),hospital visits and hospitalizations (asthma-related) 1 year
Secondary quality of life (QoL) Quality of life will be assed using "Asthma Quality of life Questionnaire with Standardised Activities", a questionnaire developed by Elizabeth Juniper( MCSP, MSc Professor, 20 Marcuse Fields Bosham, West Sussex PO18 8NA, England) to measure the functional problems (physical, emotional, social and occupational) that are most troublesome for patients with asthma. There are 32 questions in the questoinnaire and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). Patients are asked during the previous two weeks and to respond to 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). Scores range 1-7, higher scores indicating better quality of life. The better outcome is of higher score value, 0 (totally controlled), 6 (severely uncontrolled). 1 year
Secondary Eosinophil count Proportion of severe asthmatics with eosinophil count (threshold =150cells/µL and =300 cells/µL) based on current/most recent blood eosinophil level during the past year. 1 year
Secondary level of blood eosinophil. Mean or median level of blood eosinophil during the past year. 1 Year
Secondary Total serum IgE Mean or median levels of total serum IgE during the past year. 1 Year
Secondary Pre-bronchodilator forced expiratory volume Pre-bronchodilator forced expiratory volume in 1 sec 1 Year
Secondary Post-bronchodilator forced expiratory volume Post-bronchodilator forced expiratory volume in 1 sec 1 Year
Secondary Pre-bronchodilator expiratory forced vital capacity Pre-bronchodilator expiratory forced vital capacity in 1 sec 1 Year
Secondary Post-bronchodilator forced vital capacity Post-bronchodilator forced vital capacity in 1 sec 1 Year
See also
  Status Clinical Trial Phase
Recruiting NCT05018299 - Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma Phase 2
Recruiting NCT05472324 - Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. Phase 2
Recruiting NCT04914078 - Severe Asthma Exacerbations and Mepolizumab Treatment
Completed NCT05576454 - Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects Phase 1
Recruiting NCT04520165 - Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
Recruiting NCT04438408 - National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
Not yet recruiting NCT04463836 - Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
Enrolling by invitation NCT06421402 - K-HEALTH in AIR - Barcelona Pilot - Cohort
Recruiting NCT03377920 - Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's. N/A
Recruiting NCT04565483 - Predictive Signature of Benralizumab Response Phase 4
Recruiting NCT04045587 - International Severe Asthma Registry: Canadian Cohort
Completed NCT05616338 - Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC) N/A
Active, not recruiting NCT02038374 - Clinico-biological Correlation of Severe Asthma in Children N/A
Active, not recruiting NCT02114034 - Cohort Analysis of Clinical and Biological Severe Childhood Asthma
Recruiting NCT06035289 - Register Schweres Asthma - German Asthma Net e.V.
Not yet recruiting NCT03532685 - Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up N/A
Completed NCT03931954 - Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
Recruiting NCT03984253 - Swiss Severe Asthma Register
Recruiting NCT03435237 - Phenotyping Asthma for Bronchial Thermoplasty
Recruiting NCT03476109 - Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma. Phase 4

External Links